Irf2-KO Mouse
一般名
Irf2-KO
製品ID
S-KO-18938
背景情報
C57BL/6JCya
系統ID
KOCMP-16363-Irf2-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Irf2-KO Mouse(カタログ番号S-KO-18938)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Irf2-KO
系統ID
KOCMP-16363-Irf2-B6J-VB
遺伝子名
製品ID
S-KO-18938
遺伝子別名
Irf-2, 9830146E22Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 8
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000034041
NCBIトランスクリプトID
NM_008391
ターゲット領域
Exon 3
有効領域の大きさ
~1.1 kb
遺伝子研究の概要
Irf2, or interferon regulatory factor 2, is a transcription factor belonging to the IRF family. It plays diverse roles in multiple biological processes. It is involved in cytokine signaling, cell growth regulation, and hematopoietic development [4]. In the immune system, Irf2 is associated with interferon-mediated signaling pathways, which are crucial for immune activation and suppression [2,6].
In colorectal cancer, oncogenic KRASG12D (KRAS∗) represses Irf2 expression. This repression leads to high CXCL3 expression, promoting myeloid-derived suppressor cell migration to the tumor microenvironment and resulting in anti-PD-1 resistance. Enforced Irf2 expression can overcome this resistance [1]. In CD8+ T cells, deletion of Irf2 prevents T cell exhaustion within the tumor, enabling sustained effector functions and enhancing responsiveness to immune checkpoint and adoptive cell therapies [2]. In osteosarcoma, Irf2 negatively correlates with karyopherin alpha 2 (KPNA2). Irf2 binds to the KPNA2 promoter to modulate the malignant phenotypes of osteosarcoma cells [3]. For NK cells, knockdown of Irf2 greatly reduces the cell numbers of all early differentiation stages and impairs functional maturation [5]. In the context of myocardial infarction, IRF2 upregulation mediates gasdermin-D (GSDMD) induced pyroptosis [7]. Also, IRF2 is essential for GSDMD transcriptional activation, and its deficiency attenuates GSDMD expression, IL-1β secretion, and pyroptosis [8]. In melanomas, loss of Irf2 reduces MHC I pathway transcripts and causes resistance to checkpoint immunotherapy, but this can be reversed by interferon-induced IRF1 expression [9].
In conclusion, Irf2 has a wide-ranging impact on biological processes, especially in the immune system and in various diseases. Gene knockout or knockdown models in different cell types and animal models, such as mouse models, have been crucial in revealing its role in immune evasion, tumor development, cell differentiation, and pyroptosis-related pathologies. These findings provide potential targets for enhancing cancer control and treating other diseases like myocardial infarction.
References:
1. Liao, Wenting, Overman, Michael J, Boutin, Adam T, Wang, Y Alan, DePinho, Ronald A. 2019. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. In Cancer cell, 35, 559-572.e7. doi:10.1016/j.ccell.2019.02.008. https://pubmed.ncbi.nlm.nih.gov/30905761/
2. Lukhele, Sabelo, Rabbo, Diala Abd, Guo, Mengdi, McGaha, Tracy L, Brooks, David G. 2022. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. In Immunity, 55, 2369-2385.e10. doi:10.1016/j.immuni.2022.10.020. https://pubmed.ncbi.nlm.nih.gov/36370712/
3. Xia, Shuchi, Ma, Yiqun. 2022. IRF2 Destabilizes Oncogenic KPNA2 to Modulate the Development of Osteosarcoma. In Journal of oncology, 2022, 9973519. doi:10.1155/2022/9973519. https://pubmed.ncbi.nlm.nih.gov/36199790/
4. Kim, Inyoung, Kim, Jung Ha, Kim, Kabsun, Lee, Keun-Bae, Kim, Nacksung. . IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling. In BMB reports, 54, 482-487. doi:. https://pubmed.ncbi.nlm.nih.gov/34488926/
5. Persyn, Eva, Wahlen, Sigrid, Kiekens, Laura, Van Vlierberghe, Pieter, Leclercq, Georges. 2022. IRF2 is required for development and functional maturation of human NK cells. In Frontiers in immunology, 13, 1038821. doi:10.3389/fimmu.2022.1038821. https://pubmed.ncbi.nlm.nih.gov/36544762/
6. Sheikh, Amania A, Utzschneider, Daniel T. . IRF2 integrates inflammatory signals to balance T cell exhaustion. In Immunity, 55, 2225-2227. doi:10.1016/j.immuni.2022.11.010. https://pubmed.ncbi.nlm.nih.gov/36516816/
7. Li, Yongxing, Wang, Yan, Guo, Hua, Wu, Qinghua, Hu, Yamin. 2021. IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis. In Molecular medicine reports, 25, . doi:10.3892/mmr.2021.12556. https://pubmed.ncbi.nlm.nih.gov/34878155/
8. Kayagaki, Nobuhiko, Lee, Bettina L, Stowe, Irma B, Bertram, Edward M, Dixit, Vishva M. 2019. IRF2 transcriptionally induces GSDMD expression for pyroptosis. In Science signaling, 12, . doi:10.1126/scisignal.aax4917. https://pubmed.ncbi.nlm.nih.gov/31113851/
9. Sari, G, Dhatchinamoorthy, K, Orellano-Ariza, L, Brehm, M A, Rock, K. 2024. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas. In Journal of experimental & clinical cancer research : CR, 43, 276. doi:10.1186/s13046-024-03187-5. https://pubmed.ncbi.nlm.nih.gov/39354629/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
